Scott Daigle
About Scott Daigle
Scott Daigle serves as the Senior Director of Translational Medicine at Nimbus Therapeutics and has extensive experience in the pharmaceutical industry, including roles at Agios Pharmaceuticals and Servier Pharmaceuticals.
Work at Nimbus
Scott Daigle has been serving as the Senior Director of Translational Medicine at Nimbus Therapeutics since 2023. In this role, he focuses on advancing drug development strategies and enhancing translational research efforts within the organization. His extensive background in translational medicine supports Nimbus's mission to innovate in the field of drug discovery.
Current Role at Servier Pharmaceuticals
In addition to his position at Nimbus Therapeutics, Scott Daigle holds the title of Director of Translational Medicine at Servier Pharmaceuticals. He has been with Servier since 2021, contributing to the company's translational research initiatives and overseeing projects aimed at bridging the gap between preclinical and clinical development.
Previous Experience at Agios Pharmaceuticals
Before joining Servier Pharmaceuticals, Scott Daigle worked at Agios Pharmaceuticals as the Director of Translational Medicine from 2018 to 2021. During his tenure in Cambridge, MA, he played a key role in the development of innovative therapies and the implementation of translational strategies that supported clinical trials.
Educational Background
Scott Daigle earned his Master of Science in Cell and Molecular Biology from the University of New Haven, where he studied from 1999 to 2001. Prior to that, he completed his Bachelor of Science in Biology at Plymouth State University, studying from 1995 to 1999. His educational background provides a strong foundation for his work in translational medicine.
Career History in Biopharmaceuticals
Scott Daigle has a diverse career in the biopharmaceutical industry. He worked at Bayer HealthCare as a Senior Associate Scientist from 2000 to 2007, followed by a position as a Research Biologist at Merck from 2007 to 2009. His experiences in these roles contributed to his expertise in drug development and translational research.